Why did Piper Sandler initiate coverage now?

No specific reason given, but it coincides with investor interest in healthcare stocks.

Piper Sandler Initiates Thermo Fisher Coverage with Neutral

Q: Is TMO a buy right now?

The Neutral rating suggests the stock is fairly valued; investors may wait for a better entry.

Piper Sandler started covering Thermo Fisher Scientific (TMO), a top S&P 500 stock, with a Neutral rating. The analyst sees limited upside at current valuation.

June 16, 2026

2 min read

Source: Insider Monkey

Piper Sandler initiated coverage of Thermo Fisher Scientific Inc. (NYSE:TMO), which is among the 14 best S&P 500 stocks to buy now according to analysts, with a Neutral rating.

Rating Change

This is a new coverage initiation; no prior rating exists. The new rating is Neutral.

Analyst Rationale

The analyst notes that Thermo Fisher, a provider of life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, has a strong market position. However, the current valuation leaves limited upside potential in the near term, justifying a Neutral stance.

Context

The coverage comes amid investor interest in healthcare stocks as a defensive play. TMO shares have been stable recently. Other analysts have mixed ratings ranging from Buy to Hold.

What to Make of It

Piper Sandler's Neutral rating suggests the stock is fairly valued. Investors may want to wait for a better entry point or monitor upcoming quarterly results for catalysts.

Frequently Asked Questions

Neutral, as they initiate coverage.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.